BTK and non-small cell lung carcinoma: Our recent studies have revealed that ibrutinib, an irreversible inhibitor of Bruton tyrosine kinase (BTK) that was recently approved by the FDA for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia [104, 105], can function as an EGFR inhibitor to selectively inhibit growth and induce apoptosis in EGFR-mutant NSCLC cells in vitro and in vivo, including erlotinib-resistant cells that harbor a T790M mutation [106].